Compare Ginkgo Bioworks Holdings Inc (DNA) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.51 (market cap $515.15M), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.18. The key difference: Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| DNA | VCIT | |
|---|---|---|
Market Cap | $515.15M | — |
Sector | Health | Fixed Income |
52-Week High | $16.14 | $84.82 |
52-Week Low | $5.48 | $81.07 |
Enterprise Value | $617.10M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.97, down 6.24% today, reflecting ongoing operational challenges. The company reported Q2 2026 revenue of $20 million, a 48% year-over-year decline, as it shifts focus to autonomous lab systems. Despite beating EPS expectations in two of the last three quarters, net losses remain substantial with a -219.6% margin. Technical indicators show bearish momentum with support at $7 and resistance at $9.
DNA faces significant headwinds with declining revenue and persistent losses, though analyst sentiment is mixed with 45% buy ratings. The pivot to new business lines creates uncertainty, while cash burn and competitive pressures present substantial risks. Upside depends on successful execution of the strategic shift and path to profitability.
VCIT, the Vanguard Intermediate-Term Corporate Bond ETF, trades at $81.42, up 0.17% over 24 hours. The technical outlook is neutral with bearish moving averages, while recent news highlights its low 0.03% expense ratio and competitive yield. Dividend distributions are scheduled through mid-2026, providing steady income.
The ETF offers a balance of yield and moderate risk through investment-grade corporate bonds. Key risks include interest rate sensitivity and economic volatility. Analyst sentiment is mixed, emphasizing cost efficiency but cautioning on duration exposure in a shifting rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
